Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: Antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 1, 1999, Pages 37-47

  Stein, Rhona ^a   Juweid, Malik ^a   Mattes, M Jules ^a   Goldenberg, David M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

Author keywords

Animal model; Carcinoembryonic antigen; Medullary thyroid carcinoma; Monoclonal antibodies; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; IODINE 131; MONOCLONAL ANTIBODY; YTTRIUM 90;

ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CASE REPORT; DOSE RESPONSE; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; RADIOIMMUNOTHERAPY; THYROID MEDULLARY CARCINOMA; TUMOR XENOGRAFT;

EID: 0032930201     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.37     Document Type: Article

References (37)

1. Norton JA, Levin B, Jensen R. Cancer of the endocrine system. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology. New York: J.B. Lippincott Co., 1989:1333-1435.
2. Cance WG, Wells SAJ. Multiple endocrine neoplasia type IIa. Curr Prob Surg 1985; 22:1-56.
3. Rossi RL, Cady B, Meissner WA, Wool MS, Sedgewick CE, Werber J. Nonfamilial medullary thyroid carcinoma. Am J of Surg 1980; 139:554-560.
4. Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrin Metab 1988; 67:801-808.
5. Schröder S, Böcker W, Baisch H, et al. Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry and DNA content. Cancer 1988; 61:806-816.
6. Chung CT, Sagerman RH, Ryoo MC, et al. External irradiation for malignant thyroid tumors. Radiol 1980; 136:753-756.
7. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Samazin D. External radiotherapy in thyroid cancer. Cancer 1985; 55:2062-2071.
8. Juweid M, Sharkey RM, Behr T, et al. Clinical evaluation of tumor targeting with the anti-CEA murine monoclonal antibody fragment I-MN-14 F(ab)2. Cancer 1996; 78:157-168.
9. Juweid M, Sharkey RM, Behr T, et al. Radioimmuno-therapy of medullary thyroid carcinoma with I-131-labeled anti-CEA antibodies. J Nucl Med 1996; 37:905-911.
10. Juweid M, Sharkey RM, Behr T, et al. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with I-131-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 1995; 55:5946s-5951s.
11. Juweid M, Sharkey RM, Behr T, et al. Improved detection of medullary thyroid carcinoma with radio-labeled antibodies to carcinoembryonic antigen. J Clin Oncol 1996; 14:1209-1217.
12. Peltier P, Curtet C, Chatal JF, et al. Radioimmuno-detection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 1993; 34:1267-1273.
13. 111In-labeled F(ab')2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma. J Clin Endocrin Metab 1992; 74:157-163.
14. Nelkin BD, Rosenfeld KI, de Bustros A, Leong SS, Roos BA, Baylin SB. Structure and expression of a gene encoding human calcitonin and calcitonin gene related peptide. Biochem Biophys Res Commun 1984; 123:648-655.
15. American Type Culture Collection. ATCC Cell Lines and Hybridomas. Rockville, MD: American Type Culture Collection, 1994:p. 174.
16. Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993; 71:3478-3485.
17. Kyriakos RJ, Shih LB, Ong GL, Patel K, Goldenberg DM, Mattes MJ. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 1992; 52:835-842.
18. Stein R, Chen S, Sharkey RM, Goldenberg DM. Murine monoclonal antibodies raised: against human non-small cell carcinoma of the lung: specificity and tumor targeting. Cancer Res 1990; 50:1330-1336.
19. Sharkey RM, Goldenberg DM, Vagg R, et al. Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas. Cancer 1994; 73:864-877.
20. McConahey PJ, Dixon FJ. A method of trace iodination of proteins for immunologie studies. Int Arch Allergy 1966; 29:185-189.
21. Motta-Hennessy C, Sharkey RM, Goldenberg DM. Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse. J Nucl Med 1990; 31:1510-1519.
22. Cummins CH, Rutter EWJ, Fordyce WA. A convenient synthesis of bifunctional chelating agents based on diethylenetriaminepentaacetic acid and their coordination chemistry with yttrium (III). Bioconj Chem 1991; 2:180-186.
23. Brechbiel MW, Gansow OA, Atcher RW, et al. Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA; antibody labeling and tumor-imaging studies. Inorg Chem 1986; 25:2772-2781.
24. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984; 142:68-78.
25. Stein R, Chen S, Grossman W, Goldenberg DM. Human lung carcinoma monoclonal antibody specific for the Thomsen-Friedenreich antigen. Cancer Res 1989; 49:32-37.
26. Ong GL, Mattes MJ. Penetration and binding of antibodies in experimental and solid tumors. Cancer Res 1989; 49:4264-4273.
27. Stein R, Goldenberg DM, Thorpe SR, Mattes MJ. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res 1995; 55:3132-3193.
28. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 1994; 73:787-793.
29. Hanna R, Ong GL, Mattes MJ. Processing of antibodies bound to B-cell lymphomas and other hematologic malignancies. Cancer Res 1996; 56:3062-3068.
30. Stein R, Goldenberg DM, Thorpe SR, Mattes MJ. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small cell carcinoma of the lung. J Nucl Med 1997; 38:391-395.
31. Rubin P, Casarett GW. Clinical Radiation Pathology. Philadelphia: W. B. Saunders, 1968.
32. Blumenthal RD, Sharkey RM, Kashi R, Goldenberg DM. Comparison of therapeutic efficacy and host toxicity of two different 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model. Int J Cancer 1989; 44:292-300.
33. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res 1995; 55:5935s-5945s.
34. Behr TM, Wulst E, Radetzky S, et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type. Cancer Res 1997; 57:5309-5319.
35. Sharkey RM, Motta-Hennessy C, Pawlyk D, Siegal JA, Goldenberg DM. Biodistribution and radiation dose estimates for yttrium-and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 1990; 50:2330-2336.
36. Stein R, Chen S, Haim S, Goldenberg DM. Advantage of 90Y-over 131I-labeled monoclonal antibodies in the therapy of a human lung cancer xenograft. Cancer 1997; 80:2636-2641.
37. Sharkey RM, Blumenthal RD, Behr TM, et al. Selection of radioimmunoconjugates for the therapy of well-established or micrometastatic colon cancer. Int J Cancer 1997; 73:477-485.